Spotlight On... Novartis' troubled Alcon unit recalls eye drops for sterility, potency problems; Endo tanks on women's health sale; AZ sells rights to constipation drug; Denmark vies for EMA; and more...
Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
Thomas Glanzmann - Director at Alcon | The Org
Untitled
Mike Ball, Alcon Inc: Profile and Biography - Bloomberg Markets
Michael Ball | LinkedIn
Alcon - Governance - Board of Directors
2021 Annual Report Wrapper
F. Michael Ball — CEO, Alcon at Novartis | Comparably
Alcon - Governance - Board of Directors
Michael F. Land - Wikipedia
Alcon's top executive is out as eye-care sales plummet | Fort Worth Star-Telegram
Michael Onuscheck Net Worth (2023) | wallmine
Meet Our Board - Ophthalmology Foundation
Meet Our Board - Ophthalmology Foundation
Alcon CEO And Leadership: Executives and Demographics - Zippia
Alcon Announces Results of 2023 Annual General Meeting
An Investment Review of Alcon Inc. Since Its Spin-off from Novartis
F. Michael Ball News & Articles | Crain's Chicago Business
Thomas Glanzmann - Director at Alcon | The Org
Alcon - Governance - Board of Directors
Michael Francis Land. 12 April 1942—14 December 2020 | Biographical Memoirs of Fellows of the Royal Society
Novartis sees weak Q4 and year, and expects a 2017 repeat, putting Alcon's future in question | Fierce Pharma
ALCC.S - | Stock Price & Latest News | Reuters
17. Alcon (Novartis AG) | Medical Product Outsourcing
Alcon CEO And Leadership: Executives and Demographics - Zippia
Alcon CEO And Leadership: Executives and Demographics - Zippia